Five variants produced by well-known cancer gene NRAS
4/10/2014
A new study shows that a gene discovered 30 years ago and now known to play a fundamental role in cancer development produces five different gene variants (called isoforms), rather than just the one...
Trial identifies breast cancer patients likely to benefit from experimental drug
4/10/2014
In an innovative clinical trial led by UC San Francisco, the experimental drug neratinib along with standard chemotherapy was found to be a beneficial treatment for some women with newly diagnosed...
Added benefit not proven in three further subpopulations because appropriate comparator therapies were not implementedThe antibody-drug conjugate trastuzumab emtansine (trade name: Kadcyla) has...
Patients over 65 have more complications after colorectal cancer surgery
4/09/2014
Most colorectal cancer surgeries are performed on patients older than 65 years, and older patients have worse outcomes than younger patients, although the total number of colon cancer operations...
Scientists find link between brain development and breast cancer gene
4/09/2014
Mutations in the BRCA1 gene are known to increase the risk of breast and ovarian cancer. Now, researchers have uncovered a link between this gene and brain development.
Gut bacteria may encourage colon cancer by suppressing DNA repair
4/09/2014
Research suggests gut bacteria may promote cancer by changing the environment of tumors in ways that help them grow and spread, such as by making proteins that prevent DNA repair.
Arno Therapeutics, Inc., a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, has announced that it has enrolled the first patient in a Phase I/II trial...
Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has announced that a poster presentation detailing significant decrease in melanoma cells...
Among patients with advanced non-small cell lung cancer without a mutation of a certain gene (EGFR), conventional chemotherapy, compared with treatment using epidermal growth factor receptor...
Gardasil® approved in the European Union for a 2-dose schedule in children aged from 9 to 13 years
4/09/2014
Sanofi Pasteur MSD has announced that the European Commission has granted marketing authorization for its quadrivalent Human Papillomavirus (HPV) vaccine, Gardasil®, for a 2-dose schedule at 0...